Therefore, the pharmacologic management of the bleeding risk relies primarily on tranexamic acid (TXA), adapted in case of renal insufficiency, human recombinant activated FVII (rFVIIa), FXI plasma concentrates (Hemoleven), and/or fresh frozen plasma (FFP) [14]. Here, F11 is linked to Renal insufficiency.